The present disclosure provides methods of treating diabetic conditions, restoring insulin sensitivity and/or improving regulation of glycemia using an antagonist of VEGF-B, particularly in combination with other anti-diabetic agents such as insulin secretagogues. Compositions are also provided comprising one or more VEGF-B antagonists, particularly in combination with other anti-diabetic agents such as insulin secretagogues. In particular embodiments, the VEGF-B antagonist is an anti-VEGF-B antibody. In further particular embodiments, the other anti-diabetic agent or insulin secretagogue is a DPP-4 inhibitor or a GLP-1R agonist.
